Piperaquine is an antiparasitic drug used in combination with dihydroartemisinin to treat malaria. Piperaquine was developed under the Chinese National Malaria Elimination Programme in the 1960s and was adopted throughout China as a replacement for the st + some more technical info. Chemically it is a bisquinoline compound supplied commonly as the tetraphosphate salt for oral administration; it is highly lipophilic with a large volume of distribution and a long terminal elimination half-life on the order of weeks, which provides extended post-treatment prophylaxis but also demands attention to drug interactions and cardiotoxicity risk. In clinical use piperaquine is formulated only as part of artemisinin-based combination therapy to provide a rapidly acting artemisinin component and a longer acting partner drug, minimizing selection for resistance. Key safety and quality considerations include dose-related QT interval prolongation, monitoring of electrolytes and concomitant QT-prolonging medicines, controlled manufacturing to limit related impurities, and formulation strategies to ensure bioavailability and stability.
![N-(3-(Aminomethyl)benzyl)-8-(4-benzylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-amine](https://veeprho.com/wp-content/uploads/2024/10/VE0022092-N-3-Aminomethyl-benzyl-8-4-benzylpiperazin-1-yl-pyrimido-5-4-d-pyrimidin-4-amine.png "N-(3-(Aminomethyl)benzyl)-8-(4-benzylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-amine")
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Parent: Piperaquine
Impurity control is focused on synthetic related compounds, N-oxide derivatives, dealkylation products, positional isomers and residual solvents, as well as trace heavy metals; these are typically monitored by HPLC, LC-MS and validated dissolution and assay methods. Typical specification targets used in quality control are that individually identified related compounds are controlled generally below 0.2 to 0.5 percent w/w and that total impurities are kept below about 1.0 percent w/w, with lower limits applied for any impurity of toxicological concern; genotoxic or mutagenic impurities are managed according to ICH guidance and set at substantially lower thresholds. Release testing also includes identification limits, water content, residual solvent thresholds and microbial limits when relevant to the finished product.
No, Piperaquine is a bisquinoline antimalarial different in chemical class and pharmacokinetics from chloroquine, which is a 4-aminoquinoline. They have different resistance profiles, dosing regimens and safety considerations, and piperaquine is used primarily as the long-acting partner in artemisinin-based combination treatment rather than as a monotherapy.
Piperaquine interferes with parasite heme detoxification in the Plasmodium digestive vacuole, reducing conversion of toxic free heme into inert hemozoin and causing accumulation of toxic heme species; this disrupts parasite metabolism and integrity. Its long elimination half-life provides prolonged exposure that helps prevent recrudescence when paired with a fast-acting artemisinin derivative.
Pruritus has been reported but is not among the most common adverse effects; more commonly observed effects include nausea, headache and, importantly, QT interval prolongation in susceptible patients. If itching or any hypersensitivity occurs, evaluate for alternative causes and consider discontinuation and medical assessment.
Primaquine is an 8-aminoquinoline used principally for radical cure of Plasmodium vivax and Plasmodium ovale by eradicating hepatic hypnozoites and for gametocytocidal activity against Plasmodium falciparum. Primaquine can cause hemolysis in individuals with G6PD deficiency, so screening for G6PD status is required prior to treatment.
